|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Pipeline Insight: Neuropathic Pain - Emerging drugs fail...
Analysis of drugs in late-stage clinical development for use in neuropathic pain, including important clinical trial results, patient potential, market potential, and indication-specific forecasts; supported by key opinion leader comments.
Pipeline and Commercial Insight: Neuropathic Pain
This report provides full analysis of the current and future neuropathic pain market, with indication-specific sales forecasts to 2017 of marketed brands, generics, and key pipeline drugs in the US, 5EU, and Japan.
Stakeholder Opinions: Endometriosis
Endometriosis is a painful, menstrual-related disorder that is thought to affect approximately 10% of the female population of reproductive age. Despite this large patient potential, growth of the endometriosis market has been limited by low levels of
Peripheral Neuropathy and Neuropathic Pain, 2008
This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the
Commercial Insight: Migraine - Opportunities will exist
Detailed analysis of the migraine market, including an assessment of country-specific events and company strategies. Includes an indication specific ten-year forecast for marketed products across the seven major markets (7MM).
Commercial Insight: Pain Market Overview
Analysis of key market trends and growth areas in the current and future prescription pain drug market sector with quantitative analysis and segmentation of the market from 200407 and forecasts to 2017 at a regional and class level.
The Anti-Migraine Market 2007-2022
This report examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts.
Rimonabant: The first of the Cannabinoid blockbusters
This 190+ paged report features over 25 tables, and over 40 graphs and figures. The latest news, insights and analysis of the latest developments are included, with an in depth review of the cannabinoids market.
The Global Pain Therapeutics Market
assesses key pain management therapeutics - such as opioids, triptans, anticonvulsants, Cox-II inhibitors and traditional NSAIDs and are discussed in terms of their past, present and future value and the role they are playing in the effective managemen
Stakeholder Insight: Orthopedic Postoperative Pain
Postoperative pain can be caused by many different surgical procedures, each involving a variety of complications and physician specialties. Pain is a subjective experience for patients and it would seem that prescribing is driven by physicians` subje
Event Analysis and Response Service: Cox-2s - Cox-2 Crisis
On 30th September 2004, Merck withdrew its blockbuster drug Vioxx from the global market after trial data reinforced the suspicion that it increased the risk of cardiovascular events. Vioxx was a widely used Cox-2 selective non-steroidal anti-inflamma
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail
The neuropathic pain market has traditionally been a poorly defined area, with widely varying drug classes prescribed. With many drugs now in clinical trials for key neuropathic pain sub-types, pharma companies with powerful marketing arms are expecte
Postoperative Pain: Dynastat Cutting Up The Pain Market
Despite being recognized as one of the most common types of pain, few drugs have gained a specific indication for postoperative pain. With most patients still receiving inadequate postoperative pain relief, there is a significant opportunity for manufa
Stakeholder Opinions: Migraine - Lots of Experience...
Headache is the most common complaint seen in family practice in the US, yet medical training gives little time to its diagnosis and treatment. Enabling improved diagnosis and an understanding of suitable treatment pathways for migraine will allow phar
Stakeholder Insight: HIV Related Neuropathic Pain
Fueled by the growing interest in neuropathic pain but keen to avoid competition with larger players, small companies recognize the commercial opportunity of the HIV-related neuropathic pain (HIVNP) market. Not only does HIVNP offer a well-served pati
Stakeholder Insight: Neuropathic Low Back Pain
Despite millions of patients worldwide, not one neuropathic pain drug company is prioritizing the neuropathic low back pain (NLBP) market. The problem is simply that this patient group is difficult to define in clinical practice. Once diagnosis is mad
Neuropathic Pain Insight - Life Beyond Gabapentin
The huge success of Pfizer`s Neurontin (gabapentin) in the neuropathic pain market has encouraged drug manufacturers to explore the potential of their inline and pipeline products in this billion-dollar therapy area. Indeed, as gabapentin finally loses
Stakeholder Insight: Neuropathic Pain
Following the success of Pfizer`s blockbuster Neurontin (gabapentin), interest in the neuropathic pain market has grown exponentially. The market will continue to grow unabated over the next ten years primarily due to increased public and physician aw
The Pain Market Outlook to 2011
Across the seven major markets, it is forecast that the prevalence of both the neuropathic and nociceptive markets will increase modestly. It is forecast that the prevalence of the neuropathic pain market will increase to 39.1m individuals, which is c
Commercial Insight: Neuropathic Pain
Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion. However, Pfizer’s follow-on Lyrica (pregabalin), Lilly’s Cymbalta (duloxetine) and Endo/Elan’s Lidoderm (lidocaine patch 5%) ar
Pipeline Insight: Breakthrough Pain
In spite of generic Actiq competition, Cephalon’s reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics will enter the arena and
Pipeline Insight: Migraine
After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains re
Results 1 - 24 of 24
|
|
|
|
|
|
